Advances in pharmacotherapy

treatment of HIV infection

Courtney V Fletcher, E. P. Acosta

Research output: Contribution to journalReview article

Abstract

Current estimates indicate that at least one million people in the United States, 500 000 in Western Europe and perhaps six million individuals in sub‐Saharan Africa are infected by the human immunodeficiency virus (HIV), the virus that causes the acquired immunodeficiency syndrome (AIDS). This article summarizes recent developments in the study and clinical application of agents directed against HIV. There are presently four primary targets in the life‐cycle of HIV for interruption of replication. Of these, only the inhibition of reverse transcriptase by drugs such as zidovudine, didanosine and zalcitabine has been shown to be clinically beneficial. Zidovudine is the drug with which we have the greatest experience, and it remains the cornerstone of anti‐HIV therapy. Even so, there is much that remains to be learned about zidovudine and other dideoxy‐nucleoside agents regarding the clinical meaning of HIV‐resistance, and the ideal time to initiate therapy. Putative anti‐HIV compounds such as non‐nucleoside reverse transcriptase inhibitors, for inhibitors and protease inhibitors are currently under investigation. The development of these compounds, with mechanisms of action different from dideoxynucleosides, represents exciting prospects for combination therapy.

Original languageEnglish (US)
Pages (from-to)375-388
Number of pages14
JournalJournal of Clinical Pharmacy and Therapeutics
Volume18
Issue number6
DOIs
StatePublished - Jan 1 1993

Fingerprint

Virus Diseases
Zidovudine
Dideoxynucleosides
HIV
Drug Therapy
Zalcitabine
Didanosine
Reverse Transcriptase Inhibitors
Africa South of the Sahara
RNA-Directed DNA Polymerase
Therapeutics
Virus Replication
Protease Inhibitors
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Advances in pharmacotherapy : treatment of HIV infection. / Fletcher, Courtney V; Acosta, E. P.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 18, No. 6, 01.01.1993, p. 375-388.

Research output: Contribution to journalReview article

@article{3b9f622c58f54ce683cbd3bd5ccea668,
title = "Advances in pharmacotherapy: treatment of HIV infection",
abstract = "Current estimates indicate that at least one million people in the United States, 500 000 in Western Europe and perhaps six million individuals in sub‐Saharan Africa are infected by the human immunodeficiency virus (HIV), the virus that causes the acquired immunodeficiency syndrome (AIDS). This article summarizes recent developments in the study and clinical application of agents directed against HIV. There are presently four primary targets in the life‐cycle of HIV for interruption of replication. Of these, only the inhibition of reverse transcriptase by drugs such as zidovudine, didanosine and zalcitabine has been shown to be clinically beneficial. Zidovudine is the drug with which we have the greatest experience, and it remains the cornerstone of anti‐HIV therapy. Even so, there is much that remains to be learned about zidovudine and other dideoxy‐nucleoside agents regarding the clinical meaning of HIV‐resistance, and the ideal time to initiate therapy. Putative anti‐HIV compounds such as non‐nucleoside reverse transcriptase inhibitors, for inhibitors and protease inhibitors are currently under investigation. The development of these compounds, with mechanisms of action different from dideoxynucleosides, represents exciting prospects for combination therapy.",
author = "Fletcher, {Courtney V} and Acosta, {E. P.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1111/j.1365-2710.1993.tb00875.x",
language = "English (US)",
volume = "18",
pages = "375--388",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Advances in pharmacotherapy

T2 - treatment of HIV infection

AU - Fletcher, Courtney V

AU - Acosta, E. P.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Current estimates indicate that at least one million people in the United States, 500 000 in Western Europe and perhaps six million individuals in sub‐Saharan Africa are infected by the human immunodeficiency virus (HIV), the virus that causes the acquired immunodeficiency syndrome (AIDS). This article summarizes recent developments in the study and clinical application of agents directed against HIV. There are presently four primary targets in the life‐cycle of HIV for interruption of replication. Of these, only the inhibition of reverse transcriptase by drugs such as zidovudine, didanosine and zalcitabine has been shown to be clinically beneficial. Zidovudine is the drug with which we have the greatest experience, and it remains the cornerstone of anti‐HIV therapy. Even so, there is much that remains to be learned about zidovudine and other dideoxy‐nucleoside agents regarding the clinical meaning of HIV‐resistance, and the ideal time to initiate therapy. Putative anti‐HIV compounds such as non‐nucleoside reverse transcriptase inhibitors, for inhibitors and protease inhibitors are currently under investigation. The development of these compounds, with mechanisms of action different from dideoxynucleosides, represents exciting prospects for combination therapy.

AB - Current estimates indicate that at least one million people in the United States, 500 000 in Western Europe and perhaps six million individuals in sub‐Saharan Africa are infected by the human immunodeficiency virus (HIV), the virus that causes the acquired immunodeficiency syndrome (AIDS). This article summarizes recent developments in the study and clinical application of agents directed against HIV. There are presently four primary targets in the life‐cycle of HIV for interruption of replication. Of these, only the inhibition of reverse transcriptase by drugs such as zidovudine, didanosine and zalcitabine has been shown to be clinically beneficial. Zidovudine is the drug with which we have the greatest experience, and it remains the cornerstone of anti‐HIV therapy. Even so, there is much that remains to be learned about zidovudine and other dideoxy‐nucleoside agents regarding the clinical meaning of HIV‐resistance, and the ideal time to initiate therapy. Putative anti‐HIV compounds such as non‐nucleoside reverse transcriptase inhibitors, for inhibitors and protease inhibitors are currently under investigation. The development of these compounds, with mechanisms of action different from dideoxynucleosides, represents exciting prospects for combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027717980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027717980&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2710.1993.tb00875.x

DO - 10.1111/j.1365-2710.1993.tb00875.x

M3 - Review article

VL - 18

SP - 375

EP - 388

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 6

ER -